Insider · CIK 0001610381

Vivaldi Coelho Rogerio

Reports to the SEC for 6 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001610381

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−13.3K sh	$85.00	−$1.13M	5,925
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−5,925 sh	$85.00	−$504K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−35K sh	$56.69	−$1.98M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,750 sh	$66.71	−$584K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−17.5K sh	$64.68	−$1.13M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.5K sh	$40.29	−$504K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	$52.67	−$545K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−9,730 sh	$49.13	−$478K	0
2026-07-02	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Director	SSale	−3,000 sh	$40.00	−$120K	19,225
2026-06-18	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+5,925 sh	—	—	22,225
2026-06-18	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+9,730 sh	—	—	9,730
2026-03-12	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Director	SSale	−4,477 sh	$36.08	−$162K	16,823
2026-03-12	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Director	SSale	−523 sh	$36.77	−$19.2K	16,300
2026-03-06	VTRSViatris IncM Exercise/Conversion	Director	MExercise/Conversion	+23.7K sh	—	—	45,351
2026-03-06	VTRSViatris IncM Exercise/Conversion	Director	MExercise/Conversion	+1,175 sh	—	—	46,526
2026-03-06	VTRSViatris Inc · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−23.7K sh	—	—	0
2026-03-06	VTRSViatris Inc · Dividend Equivalent UnitsM Exercise/Conversion	Director	MExercise/Conversion	−1,174.492 sh	—	—	0
2026-03-06	VTRSViatris Inc · Restricted Stock UnitsA Award	Director	AAward	+15.9K sh	—	—	15,890
2025-06-11	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+6,900 sh	—	—	21,300
2025-06-11	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+10.4K sh	—	—	10,350
2025-03-06	VTRSViatris Inc · Restricted Stock UnitsA Award	Director	AAward	+23.7K sh	—	—	23,660
2025-03-04	VTRSViatris IncM Exercise/Conversion	Director	MExercise/Conversion	+21.3K sh	—	—	21,267
2025-03-04	VTRSViatris IncM Exercise/Conversion	Director	MExercise/Conversion	+424 sh	—	—	21,691
2025-03-04	VTRSViatris Inc · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−21.3K sh	—	—	0
2025-03-04	VTRSViatris Inc · Dividend Equivalent UnitsM Exercise/Conversion	Director	MExercise/Conversion	−423.013 sh	—	—	0
2024-06-07	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+3,400 sh	—	—	14,400
2024-06-07	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2024-06-03	VTRSViatris Inc · Restricted Stock UnitsA Award	Director	AAward	+21.3K sh	—	—	21,267
2023-08-11	Sigilon Therapeutics, Inc.D Disposition to Issuer	Director, PRESIDENT AND CEO	DDisposition to Issuer	−12.2K sh	—	—	0
2023-08-11	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director, PRESIDENT AND CEO	DDisposition to Issuer	−35.4K sh	$0.75	−$26.5K	0
2023-07-21	Sigilon Therapeutics, Inc.M Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	+5,528 sh	$19.24	+$106K	11,963
2023-07-21	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, PRESIDENT AND CEO	MExercise/Conversion	−5,528 sh	—	—	12,163
2023-06-16	CRNXCrinetics Pharmaceuticals, Inc.A Award	Director	AAward	+6,000 sh	—	—	11,000
2023-06-16	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+17.5K sh	—	—	17,500
2023-06-08	CRNXCrinetics Pharmaceuticals, Inc.P Purchase	Director	PPurchase	+5,000 sh	$22.06	+$110K	5,000
2023-02-28	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, PRESIDENT AND CEO	AAward	+460K sh	—	—	460,000
2022-06-17	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+8,750 sh	—	—	8,750
2022-02-18	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, PRESIDENT AND CEO	AAward	+230K sh	$1.48	+$340K	230,000
2022-01-03	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+35K sh	—	—	35,000
2022-01-03	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+25K sh	—	—	25,000
2022-01-03	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, PRESIDENT AND CEO	AAward	+400K sh	$3.03	+$1.21M	400,000
2021-11-04	Sigilon Therapeutics, Inc.A Award	Director, PRESIDENT AND CEO	AAward	+50K sh	—	—	73,461
2021-02-11	Sigilon Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director, PRESIDENT AND CEO	AAward	+200K sh	—	—	200,000
2020-12-08	Sigilon Therapeutics, Inc.C Conversion	Director, PRESIDENT AND CEO	CConversion	+22.2K sh	—	—	22,222
2020-12-08	Sigilon Therapeutics, Inc.Series B Convertible Preferred StockC Conversion	Director, PRESIDENT AND CEO	CConversion	−22.2K sh	—	—	0
2018-03-08	Bioverativ Inc.D Disposition to Issuer	EVP, Chief Global Therapeutics	DDisposition to Issuer	−5,758.041 sh	—	—	0
2018-03-08	Bioverativ Inc.Restricted Stock UnitsD Disposition to Issuer	EVP, Chief Global Therapeutics	DDisposition to Issuer	−14.2K sh	—	—	0
2018-03-08	Bioverativ Inc.Restricted Stock UnitsD Disposition to Issuer	EVP, Chief Global Therapeutics	DDisposition to Issuer	−42.7K sh	—	—	0
2018-03-08	Bioverativ Inc.Non-Qualified Stock OptionD Disposition to Issuer	EVP, Chief Global Therapeutics	DDisposition to Issuer	−113K sh	—	—	0
2018-03-08	Bioverativ Inc.Non-Qualified Stock OptionD Disposition to Issuer	EVP, Chief Global Therapeutics	DDisposition to Issuer	−56.6K sh	—	—	0

Recent filings

Accepted (ET)
Sep 14
Vivaldi Coelho Rogerio0001628280-26-059907
SEC(opens sec.gov)
Jul 74
Vivaldi Coelho Rogerio0001628280-26-047507
SEC(opens sec.gov)
Jun 224
Vivaldi Coelho Rogerio0001628280-26-044714
SEC(opens sec.gov)
Mar 134
Vivaldi Coelho Rogerio0001628280-26-017797
SEC(opens sec.gov)
Mar 104
Vivaldi Coelho Rogerio0001140361-26-008884
SEC(opens sec.gov)
Jun 134
Vivaldi Coelho Rogerio0000950170-25-086268
SEC(opens sec.gov)

Companies

Address

C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD

SAN DIEGO, CA, 92121